Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 826

Sort by

Sort Order Select

Journal Articles

bcr3 PML-RARA : short fusion, small blasts!

Moe R. Takeda, Sandeep Gurbuxani

Blood (2021) 137 (19): 2708.

https://doi.org/10.1182/blood.2021010965

Published: 2021

Journal Articles

PML-RARα: changing myeloid networks

Scott C. Kogan

Blood (2021) 137 (11): 1439–1440.

https://doi.org/10.1182/blood.2020008849

Published: 2021

Journal Articles

A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia

Yun Tan, Xiaoling Wang, Huan Song, Yi Zhang, Rongsheng Zhang, Shufen Li, Wen Jin, Saijuan Chen, Hai Fang, Zhu Chen, Kankan Wang

Blood (2021) 137 (11): 1503–1516.

https://doi.org/10.1182/blood.2020005698

Published: 2021

Includes: Supplemental data

Journal Articles

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Ilaria Iacobucci, PhD, Manja Meggendorfer, PhD, Niroshan Nadarajah, Stanley Pounds, PhD, Lei Shi, PhD, Chunxu Qu, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Charles G. Mullighan, MBBS, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2019-132746

Published: 2019

Journal Articles

A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment

Fernanda Marconi Roversi, Maura Lima Pereira Bueno, undergraduate, Cristiane Okuda Torello, PhD, Fernanda I Della Via, MSc, Renata Giardini Rosa, PhD, Juares Ednaldo Romero Bianco, PhD, Adriana Silva Santos Duarte, PhD, Eduardo M Rego, MD PhD, Alessio Molinari, Maurizio Botta, Sara T Olalla Saad, PhD

Blood (2019) 134 (Supplement_1): 4650.

https://doi.org/10.1182/blood-2019-128959

Published: 2019

Journal Articles

Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, MS, Nicola Long, Anupriya Agarwal, PhD, Cristina E. Tognon, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 878.

https://doi.org/10.1182/blood-2019-126020

Published: 2019

Journal Articles

Application of RNA Sequencing Detects a Large Number of Novel Fusion Transcripts in Patients with AML and MDS

Anna Stengel, PhD, Rabia Shahswar, MD, Wencke Walter, PhD, Manja Meggendorfer, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2019) 134 (Supplement_1): 887.

https://doi.org/10.1182/blood-2019-124310

Published: 2019

Journal Articles

Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?

Hassan Awada, MD, Jibran Durrani, Tariq Zuheir Kewan, MD, Ashwin Kishtagari, MBBS, Valeria Visconte, PhD, Reda Z. Mahfouz, MD PhD

Blood (2019) 134 (Supplement_1): 1404.

https://doi.org/10.1182/blood-2019-131724

Published: 2019

Journal Articles

Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma

Alison J. Moskowitz, MD, Heiko Schoder, MD, Jisun Lee, Theresa Davey, MMSc, PA-C, Helen Hancock, ANP, Paul A. Hamlin, MD, Steven M. Horwitz, MD, Anita Kumar, MD, Matthew J Matasar, MD, Ariela Noy, MD, M. Lia Palomba, MD, Gunjan L. Shah, MDMS, Miguel-Angel Perales, MD, Craig S. Sauter, MD, David J. Straus, MD, Anas Younes, MD, Andrew D. Zelenetz, MD PhD, Joachim Yahalom, MD, Craig H. Moskowitz

Blood (2019) 134 (Supplement_1): 1555.

https://doi.org/10.1182/blood-2019-129364

Published: 2019

Journal Articles

Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia

Blood (2019) 134 (Supplement_1): 2719.

https://doi.org/10.1182/blood-2019-131211

Published: 2019

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, MD, Bruce D. Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, MD, Uwe H Hahn, MD, Eliza A Hawkes, Cyrus Khan, MD, Izidore S. Lossos, MD, Gerardo Musuraca, MD PhD, Monica Tani, Umberto Vitolo, Sam Lung Sang Yuen, MBBS,FRCPA,FRACP, Aparna Raval, PhD, Mahesh R. Shivhare, PhD, Tina G Nielsen, MD PhD, Gila Sellam, PhD, Jeff P. Sharman, MD

Blood (2019) 134 (Supplement_1): 2874.

https://doi.org/10.1182/blood-2019-123368

Published: 2019

Journal Articles

R-m-NHL-BFM-90/R-EPOCH Protocol in the Treatment of Patients with Primary Mediastinal Lymphoma: First Results

Nelly G Gabeeva, PhD, Darya A Koroleva, Svetlana A Tatarnikova, Anna K Smolyaninova, Svetlana Smirnova, MD PhD, Elena E Nikulina, Alla M. Kovrigina, MD PhD, Andrey B Sudarikov, PhD DSc, Eugene E. Zvonkov, MD PhD, Valery G. Savchenko, MD PhD academician

Blood (2019) 134 (Supplement_1): 5334.

https://doi.org/10.1182/blood-2019-127944

Published: 2019

Journal Articles

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

Judah Friedman, MD, Hun Ju Lee, MD, Linda Ho, Ian W. Flinn, MD PhD

Blood (2019) 134 (Supplement_1): 2836.

https://doi.org/10.1182/blood-2019-122969

Published: 2019

Journal Articles

Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide

Jorge Monge, MD, Jorge Contreras, MD, Sarah Elsoukkary, MD, Jin Guo, MD, Art Perry, PA, Robin S. Solomon, Kari Flicker, BS, David S Jayabalan, MSc, Morton Coleman, MD, Adriana C. Rossi, MDMSc, Rebecca Harris, MD, Markus Plate, MD, Joerg-Patrick Stuebgen, MB, ChB, MD, Ruben Niesvizky, MD

Blood (2019) 134 (Supplement_1): 4876.

https://doi.org/10.1182/blood-2019-122134

Published: 2019

Journal Articles

Reduced SLIT2 Are Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in APL Cells

Isabel Weinhäuser, MSc, Diego A Pereira-Martins, MSc, Luíse A A Simões, BSc, César Alexander Ortiz Rojas, BSc, Thiago Mantello Bianco, MSc, Cleide Lucia Silva, MSc, Mariane Cristina Do Nascimento, BSc, Lorena Lobo Figueiredo-Pontes, MD PhD, Antonio R. Lucena-Araujo, PhD, Eduardo M Rego, MD PhD

Blood (2019) 134 (Supplement_1): 5165.

https://doi.org/10.1182/blood-2019-131496

Published: 2019

Journal Articles

BCR-ABL1+ AML De Novo and CBF-Leukemia at Relapse: Game of Clones

Olga Kulemina, MD, Nadia Siordia, MD, Konstantin Bogdanov, PhD, Julia Alexeeva, MD PhD, Larisa Girshova, MD PhD, Elza Lomaia, MD PhD, Andrey Zaritskey, MD PhD

Blood (2019) 134 (Supplement_1): 5138.

https://doi.org/10.1182/blood-2019-129815

Published: 2019

Journal Articles

Local Field Radiotherapy Induced Therapy Related Myeloid Neoplasms and Bone Marrow Suppression

Dina Sameh Soliman, MD MB, MMSc, Ahmad Al-Sabbagh, MD, Firyal Ibrahim, MD, Halima El-Omri, MD, Mohamed A Yassin, MBBS, MSc, Aliaa Amer, MD

Blood (2019) 134 (Supplement_1): 5113.

https://doi.org/10.1182/blood-2019-131683

Published: 2019

Journal Articles

Improved Outcomes of All-Trans-Retinoic Acid and Arsenic Trioxide Plus Idarubicin As a Frontline Treatment in Adult Patients with Acute Promyelocytic Leukemia

Shiwei Yang, Zunmin Zhu, Xiaojian Zhu, Yicheng Zhang

Blood (2019) 134 (Supplement_1): 5088.

https://doi.org/10.1182/blood-2019-128602

Published: 2019

Journal Articles

CUDC-101 Overcomes Arsenic Trioxide Resistance Via Caspase-Dependent PML-Rarα Degradation in Acute Promyelocytic Leukemia

Tianzhuo Zhang, Jishi Wang, PhD

Blood (2019) 134 (Supplement_1): 5054.

https://doi.org/10.1182/blood-2019-131618

Published: 2019

Journal Articles

The Presence of Minimal Residual Disease, As Determined By Highly Sensitive Quantitation of NPM1 -Mutatation, Provided Powerful Prognostic Information in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 5097.

https://doi.org/10.1182/blood-2019-127725

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

bcr3 PML-RARA : short fusion, small blasts!

PML-RARα: changing myeloid networks

A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment

Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

Application of RNA Sequencing Detects a Large Number of Novel Fusion Transcripts in Patients with AML and MDS

Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?

Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma

Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

R-m-NHL-BFM-90/R-EPOCH Protocol in the Treatment of Patients with Primary Mediastinal Lymphoma: First Results

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide

Reduced SLIT2 Are Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in APL Cells

BCR-ABL1+ AML De Novo and CBF-Leukemia at Relapse: Game of Clones

Local Field Radiotherapy Induced Therapy Related Myeloid Neoplasms and Bone Marrow Suppression

Improved Outcomes of All-Trans-Retinoic Acid and Arsenic Trioxide Plus Idarubicin As a Frontline Treatment in Adult Patients with Acute Promyelocytic Leukemia

CUDC-101 Overcomes Arsenic Trioxide Resistance Via Caspase-Dependent PML-Rarα Degradation in Acute Promyelocytic Leukemia

The Presence of Minimal Residual Disease, As Determined By Highly Sensitive Quantitation of NPM1 -Mutatation, Provided Powerful Prognostic Information in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only